Vir Biotechnology (VIR) Receivables - Accured (2020 - 2024)

Vir Biotechnology has reported Receivables - Accured for 5 years, with the latest figure at $5.7 million in Q1 2024.

• Quarterly Receivables - Accured rose 171.43% year-over-year to $5.7 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $5.7 million (up 171.43% YoY) and the FY2023 annual result came in at $4.0 million, up 60.0% from the prior year.
• Receivables - Accured advanced to $5.7 million in Q1 2024 per VIR's latest filing, from $4.0 million in the prior quarter.
• Over five years, Receivables - Accured peaked at $5.7 million in Q1 2024 and troughed at $600000.0 in Q2 2021.
• A 5-year average of $2.1 million and a median of $1.8 million in 2022 frame the typical range for Receivables - Accured.
• The widest YoY moves for Receivables - Accured: up 250.0% in 2022, down 0.0% in 2022.
• Over 5 years, Receivables - Accured stood at $800000.0 in 2020, then jumped by 37.5% to $1.1 million in 2021, then surged by 127.27% to $2.5 million in 2022, then soared by 60.0% to $4.0 million in 2023, then soared by 42.5% to $5.7 million in 2024.
• According to Business Quant data, Receivables - Accured over the past three periods registered $5.7 million, $4.0 million, and $2.9 million for Q1 2024, Q4 2023, and Q3 2023 respectively.